Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus–Infected Donors to Noninfected RecipientsChristine M. Durand, Niraj M. Desai, Darin Ostrander et al.|Annals of Internal Medicine|2018Cited by 295
The Drug Overdose Epidemic and Deceased-Donor Transplantation in the United StatesChristine M. Durand, Dorry L. Segev, Allan B. Massie et al.|Annals of Internal Medicine|2018Cited by 195
A prospective multicenter pilot study of HIV-positive deceased donor to HIV-positive recipient kidney transplantation: HOPE in actionChristine M. Durand, Dorry L. Segev, Sander Florman et al.|American Journal of Transplantation|2020Cited by 112
Changes in Utilization and Discard of Hepatitis C–Infected Donor Livers in the Recent EraMary G. Bowring, Christine M. Durand, Ahmet Gürakar et al.|American Journal of Transplantation|2016Cited by 105
Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DMRohan Khera, Marc A. Suchard, Michael B. Cook et al.|BMJ Medicine|2023Cited by 27